Prothena Corporation plc (NASDAQ: PRTA) shares were surging 43% to $15.73 in extended-hours session. The stock also suffered a loss of -11.15% over the past one month, -2.31 % loss in three months, and -10.13 % loss in six months.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Feb. 01, 2021, Prothena Corporation plc (NASDAQ: PRTA) reported that after further inquiries by the Organization and many in-depth consultations with the U.S. Food and Drug Administration, Prothena is advancing birtamimab into the confirmatory Phase 3 AFFIRM-AL trial in this group of patients with AL amyloidosis in compared to the earlier review of patients classified as Mayo Stage IV at baseline in the Detailed review.
- 3 Best Gene Therapy Stocks for long-term Investment
- Two of the Best Pharmaceutical Stocks to Watch for in 2021
This registration-enabling research, under a Special Protocol Appraisal Arrangement with the FDA, will be performed with a primary endpoint of all-cause mortality at p<0.10. Birtamimab seems to be the only experimental therapy that in a placebo-controlled trial demonstrated a substantial survival advantage in Mayo Stage IV patients with AL amyloidosis, with 74% of birtamimab-treated patients alive at 9 months versus 49% of patients in the Critical control group (hazard ratio (HR)=0.413, p=0.025, over 9 months). AFFIRM-AL is scheduled to begin in mid-2021.
Furthermore, the critical survival advantage observed for VITAL with birtamimab was accompanied by proof of clinical benefit for secondary endpoints, including significant improvements reported for both the Short Form-36 version 2 Physical Part Score (SF-36v2 PCS), the Quality of Life Calculation (p=0.026), and the 6 Minute Walk Test (6MWT), and the Adaptive Ability Evaluation (p=0.046).
In the end…
From Prothena Corporation plc’s Ownership summary, we can see that Institutional owners comprise 94.8% of its total stock ownership. In total, they own 39.92 million shares. Looking specifically at the top three stockholders, Ecor1 Capital LLC owns 9.43 million shares, followed by Fidelity Management & Research Co. LLC with 3.33 million shares and BlackRock Fund Advisors with 3.15 million shares.